Open AccessAssessment of the application for renewal of authorisation of selenium‐enriched yeast produced by Saccharomyces cerevisiae CNCM I‐3399 for all animal species
Author(s) -
Bampidis Vasileios,
Azimonti Giovanna,
Bastos Maria de Lourdes,
Christensen Henrik,
Dusemund Birgit,
Kos Durjava Mojca,
Kouba Maryline,
LópezAlonso Marta,
López Puente Secundino,
Marcon Francesca,
Mayo Baltasar,
Pechová Alena,
Petkova Mariana,
Ramos Fernando,
Sanz Yolanda,
Villa Roberto Edoardo,
Woutersen Ruud,
Anguita Montserrat,
Galobart Jaume,
Holczknecht Orsolya,
TarrésCall Jordi,
Pettenati Elisa,
Pizzo Fabiola,
Manini Paola
Publication year - 2020
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2020.6144
Subject(s) - authorization , selenium , saccharomyces cerevisiae , yeast , context (archaeology) , food science , animal species , biology , chemistry , toxicology , biochemistry , zoology , computer science , paleontology , computer security , organic chemistry
Selenium‐enriched yeast produced by Saccharomyces cerevisiae CNCM I‐3399 (selenised yeast inactivated) ( SELSAF ) is characterised as organic selenium mainly containing selenomethionine (Se‐Met, ≥ 63%). The applicant requested for the renewal of the authorisation for selenium‐enriched yeast produced by S. cerevisiae CNCM I‐3399 when used as a feed additive for all animal species. The applicant has provided evidence that the additive in the market complies with the conditions of the authorisation. The Panel on Additives and Products or Substances used in Animal Feed ( FEEDAP Panel) confirms that the use of selenium‐enriched yeast produced by S. cerevisiae CNCM I‐3399 under the current authorised conditions of use is safe for the target species, the consumers and the environment. The additive is non‐irritant to skin and eyes but should be considered a respiratory sensitiser. No conclusion can be reached on its dermal sensitising properties. The additive is hazardous by inhalation. Exposure of users by inhalation is very likely. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.